To date, no clinical (human) trials have been conducted regarding neuron stem cells (NSCs) in the treatment of MS, but a preclinical study using animal models showed that transplanted NSCs can differentiate into (become) neurons, integrate damaged tissues, and improve the mobility of sick mice.

The transplanted cells not only repaired the damaged tissues, but also dramatically decreased T-cell infiltration in the treated mice.

Although these preclinical results may be controversial, early NSC mortality after transplant and neural cell response may be responsible for beneficial effects following cell transplant. Additionally, NSCs have a low immunogenic potential for activating peripheral lymphocytes (natural killer cells, T-cells and B-cells).

Still, more pre-clinical studies are necessary before NSCs therapies are tested in a clinical setting.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

____________________

  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817403/
  2. http://link.springer.com/article/10.1007%2Fs11427-016-0114-9